Ivermax 0.8 mg/ ml Norveška - norveški - Statens legemiddelverk

ivermax 0.8 mg/ ml

chanelle pharmaceuticals manufacturing ltd - ivermektin - mikstur, oppløsning - 0.8 mg/ ml

Nitisinone Dipharma 5 mg Norveška - norveški - Statens legemiddelverk

nitisinone dipharma 5 mg

dipharma arzneimittel gmbh - nitisinon - kapsel, hard - 5 mg

Nitisinone Dipharma 10 mg Norveška - norveški - Statens legemiddelverk

nitisinone dipharma 10 mg

dipharma arzneimittel gmbh - nitisinon - kapsel, hard - 10 mg

Nitisinone Dipharma 2 mg Norveška - norveški - Statens legemiddelverk

nitisinone dipharma 2 mg

dipharma arzneimittel gmbh - nitisinon - kapsel, hard - 2 mg

Nitisinone Dipharma 20 mg Norveška - norveški - Statens legemiddelverk

nitisinone dipharma 20 mg

dipharma arzneimittel gmbh - nitisinon - kapsel, hard - 20 mg

Zepromec 5 mg/ ml Norveška - norveški - Statens legemiddelverk

zepromec 5 mg/ ml

chanelle pharmaceuticals manufacturing ltd - eprinomektin - påhellingsvæske, oppløsning - 5 mg/ ml

Ganciclovir Oresund Pharma 500 mg Norveška - norveški - Statens legemiddelverk

ganciclovir oresund pharma 500 mg

oresund pharma aps - ganciklovirnatrium - pulver til konsentrat til infusjonsvæske, oppløsning - 500 mg

Ridamec Vet 1 mg/ ml Norveška - norveški - Statens legemiddelverk

ridamec vet 1 mg/ ml

chanelle pharmaceuticals manufacturing ltd - moksidektin - mikstur, oppløsning - 1 mg/ ml

Xyrem Europska Unija - norveški - EMA (European Medicines Agency)

xyrem

ucb pharma ltd - natriumoksybat - cataplexy; narcolepsy - andre nervesystemet narkotika - behandling av narkolepsi med katapleksi hos voksne pasienter.

Bimzelx Europska Unija - norveški - EMA (European Medicines Agency)

bimzelx

ucb pharma s.a.   - bimekizumab - psoriasis - immunsuppressive - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.